CAPSTONE THERAPEUTICS ANNOUNCES TRANSACTION WITH TOTALSTONE LLC
27 mars 2020 20h00 HE
|
Capstone Therapeutics
TEMPE, Ariz., March 27, 2020 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB: CAPS) (“the Company”) RECAPITALIZATION OF AND MERGER WITH TOTALSTONE LLC In March 2020, the Company entered into an...
LipimetiX Development Announces Sub-License of Apo E Mimetic Peptide Platform to Anji Pharma, China
07 mai 2018 09h00 HE
|
Capstone Therapeutics
NATICK, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- LipimetiX Development, Inc. (“LipimetiX” or “the Company”) announced today that Anji Pharmaceuticals, Inc. (“Anji Pharma”) has entered a licensing...
Capstone Therapeutics Announces Transaction for Sale of Shares of Its Common Stock and Secured Loan
17 juil. 2017 08h00 HE
|
Capstone Therapeutics
TEMPE, Ariz., July 17, 2017 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) announced today that on July 14, 2017, BP Peptides, LLC (“Brookstone”) purchased 13,500,000...
Capstone Therapeutics Announces Profound, Rapid LDL Cholesterol Reduction in AEM-28-14 Primate Study
19 déc. 2016 11h52 HE
|
Capstone Therapeutics
TEMPE, Ariz., Dec. 19, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”)...
Capstone Therapeutics Announces That Its Joint Venture, LipimetiX Development, Inc., Has Closed a Series B-1 Preferred Stock Offering
25 août 2016 09h00 HE
|
Capstone Therapeutics
TEMPE, Ariz., Aug. 25, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s drug development joint venture (“JV”)...
Capstone Therapeutics Announces Existing Shareholder Decision Not to Extend Exclusive due Diligence Period
03 févr. 2016 15h29 HE
|
Capstone Therapeutics
TEMPE, Ariz., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“JV”) announced today...
Capstone Therapeutics Announces Loan From Existing Shareholder for Exclusive Due Diligence Period
15 déc. 2015 16h15 HE
|
Capstone Therapeutics
TEMPE, Ariz., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) (“the Company”) and LipimetiX Development, Inc., the Company’s 60% owned joint venture (“JV”) announced today...
Capstone Therapeutics Announces Allowance of U.S. Patent for Treatment of Diabetes With Apo E Mimetic Peptides
14 oct. 2015 09h00 HE
|
Capstone Therapeutics
TEMPE, Ariz., Oct. 14, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics, Inc. (OTCQB:CAPS) ("the Company") and its (60% owned) joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced...
Capstone Therapeutics Announces Second Quarter 2015 Financial Results and Operating Update Conference Call
10 août 2015 11h36 HE
|
Capstone Therapeutics
TEMPE, Ariz., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics (OTCQB:CAPS); (the "Company"), will hold a conference call and webcast on Thursday, August 13, 2015 at 4:30 pm EDT. The call may...
Capstone Therapeutics Announces Patent Application for Novel, More Potent Chimeric Apo E Mimetic Peptides
23 juil. 2015 08h00 HE
|
Capstone Therapeutics
TEMPE, Ariz., July 23, 2015 (GLOBE NEWSWIRE) -- Capstone Therapeutics Corp. (OTCQB:CAPS) ("the Company") and its joint venture affiliate, LipimetiX Development, Inc. ("JV"), announced today the...